Literature DB >> 17525722

Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells.

E L J M Smits1, P Ponsaerts, A L R Van de Velde, A Van Driessche, N Cools, M Lenjou, G Nijs, D R Van Bockstaele, Z N Berneman, V F I Van Tendeloo.   

Abstract

Leukemic cells exert immunosuppressive effects that interfere with dendritic cell (DC) function and hamper effective antileukemic immune responses. Here, we sought to enhance the immunogenicity of leukemic cells by loading them with the double-stranded (ds) RNA Toll-like receptor 3 (TLR3) ligand polyriboinosinic polyribocytidylic acid (poly(I:C)), mimicking viral infection of the tumor cells. Given the responsiveness of DC to TLR ligands, we hypothesized that the uptake of poly(I:C)-loaded leukemic cells by immature DC (iDC) would lead to DC activation. Primary acute myeloid leukemia (AML) cells and AML cell lines markedly responded to poly(I:C) electroporation by apoptosis, upregulation of TLR3 expression, enhanced expression of major histocompatibility complex (MHC) and costimulatory molecules and by production of type I interferons (IFN). Upon phagocytosis of poly(I:C)-electroporated AML cells, DC maturation and activation were induced as judged by an increased expression of MHC and costimulatory molecules, production of proinflammatory cytokines and an increase of T helper 1 (T(H)1)-polarizing capacity. These immune effects were suboptimal when AML cells were passively pulsed with poly(I:C), indicating the superiority of poly(I:C) transfection over pulsing. Our results demonstrate that poly(I:C) electroporation is a promising strategy to increase the immunogenicity of AML cells and to convert iDC into activated mature DC following the phagocytosis of AML cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525722     DOI: 10.1038/sj.leu.2404763

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

Review 1.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

2.  Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.

Authors:  Willemijn van den Ancker; Marvin M van Luijn; Jurjen M Ruben; Theresia M Westers; Hetty J Bontkes; Gert J Ossenkoppele; Tanja D de Gruijl; Arjan A van de Loosdrecht
Journal:  Cancer Immunol Immunother       Date:  2010-09-22       Impact factor: 6.968

3.  Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC.

Authors:  Eva Lion; Sébastien Anguille; Zwi N Berneman; Evelien L J M Smits; Viggo F I Van Tendeloo
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

Review 4.  The Role of Toll-Like Receptors in Hematopoietic Malignancies.

Authors:  Darlene A Monlish; Sima T Bhatt; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2016-09-28       Impact factor: 7.561

5.  Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer.

Authors:  Tal Flieswasser; Jinthe Van Loenhout; Laurie Freire Boullosa; Astrid Van den Eynde; Jorrit De Waele; Jonas Van Audenaerde; Filip Lardon; Evelien Smits; Patrick Pauwels; Julie Jacobs
Journal:  Cells       Date:  2020-06-16       Impact factor: 6.600

Review 6.  Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes.

Authors:  Luana Chiquetto Paracatu; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

7.  TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.

Authors:  Martina Damo; David S Wilson; Eleonora Simeoni; Jeffrey A Hubbell
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

Review 8.  Targeting the innate immune system as immunotherapy for acute myeloid leukemia.

Authors:  Emily Curran; Leticia Corrales; Justin Kline
Journal:  Front Oncol       Date:  2015-04-09       Impact factor: 6.244

9.  Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.

Authors:  Yosuke Kano; Takahiro Iguchi; Hiroto Matsui; Keishi Adachi; Yukimi Sakoda; Tomoya Miyakawa; Shun Doi; Shoichi Hazama; Hiroaki Nagano; Yoshiya Ueyama; Koji Tamada
Journal:  Cancer Sci       Date:  2016-04       Impact factor: 6.716

Review 10.  Toll-like receptors and their role in carcinogenesis and anti-tumor treatment.

Authors:  Anna Wolska; Ewa Lech-Marańda; Tadeusz Robak
Journal:  Cell Mol Biol Lett       Date:  2008-12-18       Impact factor: 5.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.